Medisafe 1 Technologies Appoints Tali Skoczylas as Chair of Medical Advisory Board

JERUSALEM, Israel, November 1, 2010 /PRNewswire-FirstCall/ -- Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company has appointed Dr. Tali Skoczylas as Chair of the company's medical advisory board.

Dr. Skoczylas is a fully licensed and accredited physician with 28 years experience serving as an Attending Physician in multiple New York hospitals. Skoczylas has served as Medical Director in several New York nursing homes.

In addition to his private practice in internal medicine, Skoczylas currently serves as Medical Director and Attending Physician at Resort Nursing Home in Arverne, NY; and holds the same posts at Kingsbridge Heights Rehabilitation Center in Brooklyn, NY. Skoczylas also serves as Attending Physician at Peninsula Hospital in Arverne, NY, and St. John's Episcopal Hospital South Shore in Far Rockaway, NY.

"Dr. Skoczylas brings immense experience and accumulated knowledge to our team, and we are honored to appoint him in an advisory capacity," said Jacob Elhadad, Chief Executive Officer of Medisafe 1 Technologies. "For decades, Dr. Skoczylas has himself administered medications in emergency environments, and been responsible for teams of doctors administering such medications. His advice carries tremendous weight with our product develop team."

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.

    Contact:
    JACOB ELHADAD
    CEO
    +972-524440000
    [email protected]

SOURCE Medisafe 1 Technologies Corp.